The Prevention and Early Intervention Program for Psychosis (PEPP-Montréal) is a program for young people who are experiencing an untreated first episode of psychosis.

The Psychotic Disorders Program at the Douglas Institute provides services to adults aged 18 to 65 with schizophrenia or other forms of psychoses, with the exception of the Prevention and Early Intervention Program for Psychoses (PEPP-Montréal), which is designed for people aged 14 to 30.

The Program for Dementia with Psychiatric Comorbidity (PDCP) provides superspecialized care to people of all ages who have mild to severe cognitive impairments combined with psychiatric or behavioural disorders.

Douglas Hospital was founded in 1881 by Alfred Perry and a group of Protestant clergy and Montréal citizens.

Brigitte L. Kieffer, PhD, is the new Scientific Director of the Douglas Institute Research Centre

Weiya Ma’s long-term research interest is to advance the understanding of how substances involved in the inflammation process play a role in the development of chronic pain conditions.

Pierre Étienne is a psychiatrist in the geriatric psychiatry program of the Douglas Institute. He is interested in the early development of medication and in Alzheimer's Disease.

Marcelo Berlim is mainly interested in the study and treatment of depressive disorders with the use of state-of-the-art neuromodulation techniques.

John Breitner, MD, has devoted his career to investigating factors that modify an individual’s risk of developing Alzheimer's Disease.

Ng Ying Kin uses neurochemical analyses to identify peripheral biological markers for various psychiatric disorders.